Abstract 14192: Iron Deficiency and Risk of One-year Adverse Events Following a Hospitalization for Acute Heart Failure

Hiroki Nakano(Honda (Japan)), Toshihisa Anzai(Hokkaido University), Takeshi Aiba(National Cerebral and Cardiovascular Center), Hisao Ogawa(Kumamoto University Hospital), Satoshi Honda(National Cerebral and Cardiovascular Center), Yasuyuki Honda(National Cerebral and Cardiovascular Center), Toshiyuki Nagai(Hokkaido University), Satoshi Yasuda(National Institute of Health Sciences), Kunihiro Nishimura(National Cerebral and Cardiovascular Center), Teruo Noguchi(National Cerebral and Cardiovascular Center), Yasuhide Asaumi(National Cerebral and Cardiovascular Center), Michikazu Nakai(National Cerebral and Cardiovascular Center), Kengo Kusano(National Cerebral and Cardiovascular Center), Yasuo Sugano(keiyu Hospital), Naotsugu Iwakami(Kyoto University), Varun Sundaram(University Hospitals of Cleveland)
Circulation
November 14, 2017
Cited by 0

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755